IDEAYA Biosciences (IDYA) Cash from Operations Growth (3y) (2021 - 2026)

IDEAYA Biosciences (IDYA) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 IDEAYA Biosciences 3.21 Bn 2.54 Bn - -39.25%

Historic Data

Download Data
DateValue
Mar 31, 2026 -39.25%
Dec 31, 2025 -57.03%
Sep 30, 2025 99.04%
Jun 30, 2025 -46.20%
Mar 31, 2025 -45.36%
Dec 31, 2024 -94.02%
Sep 30, 2024 -58.06%
Jun 30, 2024 -36.50%
Mar 31, 2024 -47.25%
Dec 31, 2023 -26.99%
Sep 30, 2023 -32.66%
Jun 30, 2023 -34.98%
Mar 31, 2023 -42.88%
Dec 31, 2022 -38.98%
Sep 30, 2022 -31.82%
Jun 30, 2022 -24.85%
Mar 31, 2022 -26.16%
Dec 31, 2021 -30.60%
Sep 30, 2021 -12.78%